Table Of Content

Breast Cancer Research and Treatment 30: 315, 1994. © 1994 Kluwer Academic Publishers. Printed in the Netherlands. Author index, Volume 30 Anderson TJ 153 Douglas-Jones A 213 Lanfranco C 133 Rostan MC 275 Artagaveytia N 275 Dowsett M 81 Lehiri M 233 Rutteman GR 139 Azuine MA 233 Dukes M_ 103 Levesque MA 179 Dyrhoff M 103 Lin F 263 Saez S 275 Bajetta E 127 Lippman M_ 167 Santen RJ 1 Balar DB 293 Ebeling K 283 Lonn S 147 Sarkaria JN 159 Baratta FS 243 Eliyahu D 167 Loénn U 147 Schmid W 213 Battersby S 153 Eliyahu S 167 Love RR 311 SchénbornI 283 Bhatavdekar JM 293 Elliott RL 299,305 Shah NG 293 Bhatia P 263 Erlichman C 205 Mamby CC 311 Shoenfeld Y 197 Bhide SV 233 Evans S 167 Marrinetti A 127 Silversward C 147 Bier B 213 McCoy JL 299,305 Simon C 263 Blankenstein MA 139 McKittrick R 263 Simpson ER 19 Faber JAJ 223 Bobin JY 275 Merlini L 133 Snoek E 89 Fabian CJ 263 Bocker W 213 Miglietta L 133 Stenkvist B 147 Falette N 275 Brekelmans CTM 223 Miller EM 159 Sutherland DJA 179 Ferrari L 127 Brodie AMH 1 Feyzi JM 311 Miller WR 153 Brueggemeier RW 31 Misdorp W_ 139 Telang NT 233 Fine S 205 Bulun SE 19 Moereels H 43 Teske E 139 Foekens JA 139 Buzzoni R 127 Moore WP 263 Testore F 133 Miihlemann K 201 Tétsch M 213 Gadalla T 205 Campora E 133 Mulcahy RT 159 Tranin AS 263 Galante E 127 Celio L 127 Trivedi SN 293 Gardin G 133 Ceriani RL 243 Naso C 133 Garin E 275 Cerrotta AM 127 Nilsson B 147 Vanden Bossche H 43 Ghosh N 293 Chan CM 243 Nischan P 283 Venturino A 133 Giudici S 133 Chin T 263 Noberasco C 127 Vergara G 263 Gopas J 197 Clark GM 117 Vora HH 293 Cocconi G 57 Orifice S 127 Vos JH 139 Cohen AD 197 Hassanein RS 263 Ozzello L 243 Head JF 299,305 Cohen Y 197 Warr D 205 Collette HJA 223 Paik S 167 Weiss NS 201 Cook LS 201 Jasani B 213 Parker CJ 159 Wouters W 89 Coombes RC 81 Jewell WR 263 Patel DD 293 Cornelisse CJ 139 Johnson N 263 Peeters PHM 223 YuH 179 Jordan VC 159 Plourde PV 103 De Coster R 89 Portengen H 139 Zalles C 263 Demers LM 95 Kaizer L 205 Zeiger S 263 Deurenberg JIM 223 Kamel S 263 Reed MJ 7 Zilembo N 127 Diamandis EP 179 Karelia NH 293 Repetto L 133 Zwiebel J 167 Dockhorn-Dworniczak B Kimler BF 263 Rosen N_ 167 213 Koymans LMH 43 Rosso R_ 133 Breast Cancer Research and Treatment 30: 315, 1994. © 1994 Kluwer Academic Publishers. Printed in the Netherlands. Author index, Volume 30 Anderson TJ 153 Douglas-Jones A 213 Lanfranco C 133 Rostan MC 275 Artagaveytia N 275 Dowsett M 81 Lehiri M 233 Rutteman GR 139 Azuine MA 233 Dukes M_ 103 Levesque MA 179 Dyrhoff M 103 Lin F 263 Saez S 275 Bajetta E 127 Lippman M_ 167 Santen RJ 1 Balar DB 293 Ebeling K 283 Lonn S 147 Sarkaria JN 159 Baratta FS 243 Eliyahu D 167 Loénn U 147 Schmid W 213 Battersby S 153 Eliyahu S 167 Love RR 311 SchénbornI 283 Bhatavdekar JM 293 Elliott RL 299,305 Shah NG 293 Bhatia P 263 Erlichman C 205 Mamby CC 311 Shoenfeld Y 197 Bhide SV 233 Evans S 167 Marrinetti A 127 Silversward C 147 Bier B 213 McCoy JL 299,305 Simon C 263 Blankenstein MA 139 McKittrick R 263 Simpson ER 19 Faber JAJ 223 Bobin JY 275 Merlini L 133 Snoek E 89 Fabian CJ 263 Bocker W 213 Miglietta L 133 Stenkvist B 147 Falette N 275 Brekelmans CTM 223 Miller EM 159 Sutherland DJA 179 Ferrari L 127 Brodie AMH 1 Feyzi JM 311 Miller WR 153 Brueggemeier RW 31 Misdorp W_ 139 Telang NT 233 Fine S 205 Bulun SE 19 Moereels H 43 Teske E 139 Foekens JA 139 Buzzoni R 127 Moore WP 263 Testore F 133 Miihlemann K 201 Tétsch M 213 Gadalla T 205 Campora E 133 Mulcahy RT 159 Tranin AS 263 Galante E 127 Celio L 127 Trivedi SN 293 Gardin G 133 Ceriani RL 243 Naso C 133 Garin E 275 Cerrotta AM 127 Nilsson B 147 Vanden Bossche H 43 Ghosh N 293 Chan CM 243 Nischan P 283 Venturino A 133 Giudici S 133 Chin T 263 Noberasco C 127 Vergara G 263 Gopas J 197 Clark GM 117 Vora HH 293 Cocconi G 57 Orifice S 127 Vos JH 139 Cohen AD 197 Hassanein RS 263 Ozzello L 243 Head JF 299,305 Cohen Y 197 Warr D 205 Collette HJA 223 Paik S 167 Weiss NS 201 Cook LS 201 Jasani B 213 Parker CJ 159 Wouters W 89 Coombes RC 81 Jewell WR 263 Patel DD 293 Cornelisse CJ 139 Johnson N 263 Peeters PHM 223 YuH 179 Jordan VC 159 Plourde PV 103 De Coster R 89 Portengen H 139 Zalles C 263 Demers LM 95 Kaizer L 205 Zeiger S 263 Deurenberg JIM 223 Kamel S 263 Reed MJ 7 Zilembo N 127 Diamandis EP 179 Karelia NH 293 Repetto L 133 Zwiebel J 167 Dockhorn-Dworniczak B Kimler BF 263 Rosen N_ 167 213 Koymans LMH 43 Rosso R_ 133 Breast Cancer Research and Treatment 30: 317-320, 1994. © 1994 Kluwer Academic Publishers. Printed in the Netherlands. Subject index, Volume 30 adipose tissue carcinoembryonic antigen (CEA) aromatase and extraglandular production of associations with p53, PSA, ER, and PgR estrogens 19-29 179-195 aminoglutethimide B-carotene as a first-generation aromatase inhibitor 57-80 in chemoprevention of animal mammary tumor dosage and side effects 57-80 models 233-242 mechanism 43-55 catechin (a natural plant product) androstenedione in chemoprevention of animal mammary tumor postmenopausal source of estrogens 7-17 models 233-242 aneuploidy CGS 20267 and CGS 47465 (aromatase inhibitors) in aspirated cells of high vs. low risk women mechanism 43-55 263-273 chemoprevention Arimidex® by natural plant products in animal mammary as a fourth-generation aromatase inhibitor tumor models 233-242 103-111 chemotherapy aromatase folinic acid and 5FU — phase II 205-209 gene regulation 19-29 weekly mitoxantrone/5FU/leucovorin — phase II highest in breast quadrant with tumor, and in 133-137 adipose stromal cells vs. adipocytes 19-29 coagulation role in breast tumors 7-17 no change in protein S or protein C caused by aromatase inhibitors tamoxifen (24 months) 311-314 4-hydroxyandrostenedione and increased serum cyclic AMP binding proteins IGF-I 127-132 increased total and type I in proliferating vs. non-steroidal — mechanisms 43-55 resting normal breast tissue 153-158 overview 1-6 CYP19 (aromatase) gene special issue 1-111 alternative promoter use and local elevations steroidal — mechanisms 31-42 19-29 benign breast disease DMBA-induced rat mammary tumors a risk factor for "interval cancer" in screening chemoprevention by natural plant products 233- study 223-232 242 no metallothionein overexpression 213-221 dog mammary tumors betel leaf extract no correlation of EGFR with ER, PgR, or in chemoprevention of animal mammary tumor aggressiveness 139-146 models 233-242 ductal carcinoma in situ (DCIS) biomarkers overexpression of metallothioneins 213-221 aneuploidy, ER, and EGFR in breast aspirates of high vs. low risk women 263-273 EGFR no correlation with ER, PgR, or aggressiveness CA 15-3 in dog mammary tumors 139-146 more effective as serum marker than immuno- endocrine therapy suppressive acidic protein (IAP) 197-200 aromatase inhibitors — special issue 1-111 318 Subject index, Vol. 30 endocrine therapy (cont.) gene amplification 4-hydroxyandrostenedione and increased serum PCR assay of amplification in paraffin- IGF-I 127-132 embedded tissue, and prognosis 147-152 enzyme-activated inhibitors steroidal aromatase inhibitors 31-42 height and weight epidemiology as risk factors for "interval cancer" in screening risk factor study for "interval cancers" 223-232 study 223-232 epidermal growth factor (EGF) hepatocellular carcinoma in serum, vs. prolactin as a prognostic factor no clear increase in U.S. with introduction of 293-297 tamoxifen 201-204 epidermal growth factor receptor (EGFR) HER-2/neu oncogene in aspirated cells of high vs. low risk women PCR assay of amplification in paraffin- 263-273 embedded tissue, and prognosis 147-152 mRNA by PCR, vs. ligand binding assay 4-hydroxyandrostenedione 275-282 and increased serum IGF-I 127-132 erbB-2 as a second-generation aromatase inhibitor PCR assay of amplification in paraffin- 81-87 embedded tissue, and prognosis 147-152 hyperplastic breast lesions estrogen receptor (ER) no metallothionein overexpression 213-221 associations with p53, CEA, PSA 179-195 in aspirated cells of high vs. low risk women immunohistochemistry 263-273 metallothioneins in normal and malignant breast in dog mammary tumors — no correlation with tissue 213-221 EGFR 139-146 immunology no correlation with lymphocyte immunity to lymphocyte immunity to tumor antigens — no tumor antigens 299-304 correlation with ER, PgR, iron-binding no correlation with EGFR mRNA (PCR assay) proteins 299-309 275-282 immunosuppressive acidic protein (IAP) estrogens ineffective as serum marker, cf. CA 15-3 role of locally formed estrone in breast tumors 197-200 7-17 insulin-like growth factor I (IGF-I) explaining tallness as a risk factor for "interval fadrozole (CGS 16949A) cancer"? 230 as a new non-steroidal aromatase inhibitor — increased serum levels with 4-hydroxy- phaseI 95-102 androstenedione 127-132 mechanism 43-55 in serum, vs.prolactin as a prognostic factor ferritin 293-297 no correlation with lymphocyte immunity to interval cancer tumor antigens 305-309 risk factors in screening study 223-232 fine needle aspirates iron-binding proteins aneuploidy, ER, and EGFR in breast aspirates of ferritin, transferrin — no correlation with high vs. low risk women 263-273 lymphocyte immunity to tumor antigens 5-fluorouracil (SFU) 305-309 and folinic acid — phase II 205-209 weekly with mitoxantrone, leucovorin — phase letrozole (CGS 20267) II 133-137 as a new non-steroidal aromatase inhibitor — folinic acid phaseI 95-102 and 5FU — phase II 205-209 mechanism 43-55 Subject index, Vol. 30 319 leucovorin EGFR mRNA, vs. ligand binding assay 275- weekly with mitoxantrone, 5FU — phase II 282 133-137 method to assay gene amplification in paraffin- lymphocytes embedded tissue 147-152 immunity to tumor antigens — no correlation progesterone receptor (PgR) with ER, PgR, iron-binding proteins associations with p53, CEA, PSA 179-195 299-309 in dog mammary tumors — no correlation with EGFR 139-146 mammography increased sensitivity of immunohistochemistry characteristics of "missed" breast cancers vs. ligand binding assay 299-304 223-232 no correlation with lymphocyte immunity to MCF-?7 cells tumor antigens 299-304 no change of radiation sensitivity by 4-hydroxy- prognostic factors tamoxifen 159-165 associations among p53, CEA, prostate-specific mechanism-based inhibition antigen (PSA), ER, and PgR 179-195 steroidal aromatase inhibitors 31-42 BrE-3 anti-mucin MAb epitope in paraffin menopause, artificial sections 243-261 a risk factor for "interval cancer" in screening lymphocyte immunity to tumor antigens — no study 223-232 correlation with ER, PgR, iron-binding metallothioneins proteins 299-309 overexpression in ductal carcinomas 213-221 oral contraceptive use and improved survival mitoxantrone 283-292 weekly with 5FU, leucovorin — phase II serum prolactin (preliminary study) 293-297 133-137 prolactin, serum monoclonal antibodies as a prognostic factor 293-297 BrE-3 anti-mucin in prognosis 243-261 proliferation mouse mammary tumor model (MMTV) increased total and type I cyclic AMP binding chemoprevention by natural plant products proteins, vs. resting breast 153-158 233-242 introduction of wild-type p53 genes suppresses mucins breast cancer cell growth 167-177 BrE-3 MAb epitope and prognosis 243-261 prostate-specific antigen (PSA) associations with p53, CEA, ER, and PgR 179- natural history of breast cancers 195 different risk factors for interval vs. screen- detected cancers 223-232 radiation sensitivity no change by 4-hydroxytamoxifen in MCF-7 oral contraceptives cells 159-165 and improved prognosis 283-292 risk factors aneuploidy, ER, and EGFR in breast aspirates of p53 tumor suppressor high vs. low risk women 263-273 associations with CEA, PSA, ER, and PgR for "interval cancer” in screening study 223-232 179-195 rogletimide introduction of wild-type or temperature-sensi- mechanism 43-55 tive mutant p53 genes suppresses breast cancer cell growth 167-177 polymerase chain reaction (PCR) screening competitive RT-PCR for aromatase transcripts risk factors for "interval cancer" (DOM project) 19-29 223-232 320 Subject index, Vol. 30 serum markers tumor antigens immunosuppressive acidic protein ineffective, cf. lymphocyte immunity — no correlation with CA 15-3 197-200 ER, PgR, iron-binding proteins 299-309 tumor markers tamoxifen serum immunosuppressive acidic protein and incidence of hepatocellular carcinoma — no ineffective, cf. CA 15-3 197-200 clear increase in U.S. 201-204 tumor suppressors no change of MCF-7 radiation sensitivity by introduction of wild-type p53 genes suppresses 4-hydroxytamoxifen 159-165 breast cancer cell growth 167-177 tamoxifen toxicity thrombophlebitis — no change in procoagulant vorazole protein S or protein C 311-314 as a new non-steroidal aromatase inhibitor testololactone 89-94 as a first-generation aromatase inhibitor 57-80 mechanism 43-55 transferrin pharmacology and pharmacokinetics 89-94 no correlation with lymphocyte immunity to tumor antigens 305-309 ZD1033 tumeric see Arimidex® in chemoprevention of animal mammary tumor models 233-242